A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing;
• Male or female aged ≥18 years and \<80 years on the day of signing the informed consent form.
Locations
Other Locations
China
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
RECRUITING
Nanjing
Contact Information
Primary
Chuo Tong
chuo.tong.ct1@hengrui.com
+0518-82342973
Time Frame
Start Date: 2026-02-25
Estimated Completion Date: 2027-06
Participants
Target number of participants: 108
Treatments
Experimental: HRS-7249 injection
Placebo_comparator: HRS-7249 injection placebo
Experimental: SHR-1918 injection
Placebo_comparator: SHR-1918 injection placebo
Related Therapeutic Areas
Sponsors
Leads: Fujian Shengdi Pharmaceutical Co., Ltd.